Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Hepatology
•
Viral Hepatitis
In what scenario do you screen patients with hepatitis B for hepatitis D co-infection?
Related Questions
When would you consider quantification of hepatitis B surface antigen as part of the treatment decision making process?
What role is there for the use of ursodiol in relapsing hepatitis A for management of liver enzyme abnormalities and patient symptoms?
In what scenarios do you defer treatment of a patient's hepatitis C if they are undergoing liver transplant evaluation?
What clinical scenario do you consider screening for hepatitis delta?
What kind of monitoring do you choose in patients at risk for reactivation of hepatitis B who are on immunosuppression?
What role is there for the assessment of hepatitis B virus genotype as it pertains to pharmacologic therapy and HCC screening?
How do you explain the additional risks that a transplant recipient may carry by pursuing a hepatitis C positive organ if they are negative?
All things being equal, what patient factors are you looking at in the selection of TAF or TDF in the management of hepatitis B?
When would you consider quantification of hepatitis B surface antigen as part of the treatment decision making process?
How do you approach the surveillance and serologic evaluation of a patient in whom you suspect has a hepatitis B pre-core mutant?
